Inorganic Radionuclides for Nuclear Medicine Therapy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-08-03

AUTHORS

Yun-Sang Lee , Jae Min Jeong

ABSTRACT

The most commonly used radionuclides for therapy are beta emitters which have shorter penetration depth than gamma emitters. Alpha or Auger emitters also are studied for higher efficiency within shorter range. Most of these radionuclides for therapy are metals and these should be labeled to specific ligands such as peptides or proteins via bifunctional chelating agents conjugated to them. Selection of the bifunctional chelating agents generally based on the dissociation constants with target metallic radionuclides. For the improved efficiency of radionuclide therapy, intensive studies about development of new ligands and labeling methods are required. More... »

PAGES

151-163

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/174_2012_704

DOI

http://dx.doi.org/10.1007/174_2012_704

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027629388


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehakno Jongno-go, 110-744, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehakno Jongno-go, 110-744, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Yun-Sang", 
        "id": "sg:person.01152420166.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152420166.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehakno Jongno-go, 110-744, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehakno Jongno-go, 110-744, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jeong", 
        "givenName": "Jae Min", 
        "id": "sg:person.01301360400.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301360400.94"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-08-03", 
    "datePublishedReg": "2012-08-03", 
    "description": "The most commonly used radionuclides for therapy are beta emitters which have shorter penetration depth than gamma emitters. Alpha or Auger emitters also are studied for higher efficiency within shorter range. Most of these radionuclides for therapy are metals and these should be labeled to specific ligands such as peptides or proteins via bifunctional chelating agents conjugated to them. Selection of the bifunctional chelating agents generally based on the dissociation constants with target metallic radionuclides. For the improved efficiency of radionuclide therapy, intensive studies about development of new ligands and labeling methods are required.", 
    "editor": [
      {
        "familyName": "Baum", 
        "givenName": "Richard P.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/174_2012_704", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-540-36718-5", 
        "978-3-540-36719-2"
      ], 
      "name": "Therapeutic Nuclear Medicine", 
      "type": "Book"
    }, 
    "keywords": [
      "bifunctional chelating agent", 
      "chelating agent", 
      "new ligands", 
      "metallic radionuclides", 
      "dissociation constants", 
      "short penetration depth", 
      "ligands", 
      "specific ligands", 
      "high efficiency", 
      "labeling method", 
      "emitters", 
      "improved efficiency", 
      "radionuclides", 
      "metals", 
      "constants", 
      "agents", 
      "peptides", 
      "short range", 
      "efficiency", 
      "gamma emitters", 
      "beta emitters", 
      "intensive study", 
      "Auger emitters", 
      "penetration depth", 
      "range", 
      "method", 
      "protein", 
      "radionuclide therapy", 
      "study", 
      "nuclear medicine therapy", 
      "development", 
      "alpha", 
      "selection", 
      "depth", 
      "therapy", 
      "medicine therapies"
    ], 
    "name": "Inorganic Radionuclides for Nuclear Medicine Therapy", 
    "pagination": "151-163", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027629388"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/174_2012_704"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/174_2012_704", 
      "https://app.dimensions.ai/details/publication/pub.1027629388"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_174.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/174_2012_704"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/174_2012_704'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/174_2012_704'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/174_2012_704'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/174_2012_704'


 

This table displays all metadata directly associated to this object as RDF triples.

102 TRIPLES      22 PREDICATES      60 URIs      53 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/174_2012_704 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N5dfc582828d946f7bd94f69cb4e34913
4 schema:datePublished 2012-08-03
5 schema:datePublishedReg 2012-08-03
6 schema:description The most commonly used radionuclides for therapy are beta emitters which have shorter penetration depth than gamma emitters. Alpha or Auger emitters also are studied for higher efficiency within shorter range. Most of these radionuclides for therapy are metals and these should be labeled to specific ligands such as peptides or proteins via bifunctional chelating agents conjugated to them. Selection of the bifunctional chelating agents generally based on the dissociation constants with target metallic radionuclides. For the improved efficiency of radionuclide therapy, intensive studies about development of new ligands and labeling methods are required.
7 schema:editor N227e565451714c75a6536606a77e6e88
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nf54e573222c8457ea88d0c6370da50c9
11 schema:keywords Auger emitters
12 agents
13 alpha
14 beta emitters
15 bifunctional chelating agent
16 chelating agent
17 constants
18 depth
19 development
20 dissociation constants
21 efficiency
22 emitters
23 gamma emitters
24 high efficiency
25 improved efficiency
26 intensive study
27 labeling method
28 ligands
29 medicine therapies
30 metallic radionuclides
31 metals
32 method
33 new ligands
34 nuclear medicine therapy
35 penetration depth
36 peptides
37 protein
38 radionuclide therapy
39 radionuclides
40 range
41 selection
42 short penetration depth
43 short range
44 specific ligands
45 study
46 therapy
47 schema:name Inorganic Radionuclides for Nuclear Medicine Therapy
48 schema:pagination 151-163
49 schema:productId N53ae0680925c4eedb872371200540438
50 Nae9686bf5003405282e8870bb6997c14
51 schema:publisher N81c0992e08a34fde8ace3f8ffb102de6
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027629388
53 https://doi.org/10.1007/174_2012_704
54 schema:sdDatePublished 2022-10-01T06:54
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N2b389695b6d14490a6f05a1a37b93bdf
57 schema:url https://doi.org/10.1007/174_2012_704
58 sgo:license sg:explorer/license/
59 sgo:sdDataset chapters
60 rdf:type schema:Chapter
61 N227e565451714c75a6536606a77e6e88 rdf:first N72680c5048234e3a83e6835a01e047ff
62 rdf:rest rdf:nil
63 N2b389695b6d14490a6f05a1a37b93bdf schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 N4ae9a145a5ae478597ee7baddbccf431 rdf:first sg:person.01301360400.94
66 rdf:rest rdf:nil
67 N53ae0680925c4eedb872371200540438 schema:name doi
68 schema:value 10.1007/174_2012_704
69 rdf:type schema:PropertyValue
70 N5dfc582828d946f7bd94f69cb4e34913 rdf:first sg:person.01152420166.90
71 rdf:rest N4ae9a145a5ae478597ee7baddbccf431
72 N72680c5048234e3a83e6835a01e047ff schema:familyName Baum
73 schema:givenName Richard P.
74 rdf:type schema:Person
75 N81c0992e08a34fde8ace3f8ffb102de6 schema:name Springer Nature
76 rdf:type schema:Organisation
77 Nae9686bf5003405282e8870bb6997c14 schema:name dimensions_id
78 schema:value pub.1027629388
79 rdf:type schema:PropertyValue
80 Nf54e573222c8457ea88d0c6370da50c9 schema:isbn 978-3-540-36718-5
81 978-3-540-36719-2
82 schema:name Therapeutic Nuclear Medicine
83 rdf:type schema:Book
84 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
85 schema:name Medical and Health Sciences
86 rdf:type schema:DefinedTerm
87 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
88 schema:name Clinical Sciences
89 rdf:type schema:DefinedTerm
90 sg:person.01152420166.90 schema:affiliation grid-institutes:grid.31501.36
91 schema:familyName Lee
92 schema:givenName Yun-Sang
93 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152420166.90
94 rdf:type schema:Person
95 sg:person.01301360400.94 schema:affiliation grid-institutes:grid.31501.36
96 schema:familyName Jeong
97 schema:givenName Jae Min
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301360400.94
99 rdf:type schema:Person
100 grid-institutes:grid.31501.36 schema:alternateName Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehakno Jongno-go, 110-744, Seoul, Korea
101 schema:name Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehakno Jongno-go, 110-744, Seoul, Korea
102 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...